Total Payments
$645,097
2024 Payments
$72,166
Companies
38
Transactions
1,129
Medicare Patients
10,723
Medicare Billing
$912,526
Payment Breakdown by Category
Other$560,975 (87.0%)
Travel$41,320 (6.4%)
Food & Beverage$22,349 (3.5%)
Consulting$16,680 (2.6%)
Research$3,638 (0.6%)
Education$75.26 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $541,357 | 296 | 83.9% |
| Travel and Lodging | $41,320 | 119 | 6.4% |
| Food and Beverage | $22,349 | 677 | 3.5% |
| Honoraria | $19,618 | 16 | 3.0% |
| Consulting Fee | $16,680 | 12 | 2.6% |
| Unspecified | $3,638 | 2 | 0.6% |
| Education | $75.26 | 6 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Payments by Type
General
$641,459
1,127 transactions
Research
$3,638
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $216,326 | 394 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $171,834 | 263 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $93,402 | 128 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $52,512 | 49 | $0 (2024) |
| Lilly USA, LLC | $44,462 | 69 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $32,955 | 69 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $18,146 | 21 | $0 (2022) |
| Ascendis Pharma Inc | $4,220 | 1 | $0 (2024) |
| Eli Lilly and Company | $3,638 | 2 | $0 (2024) |
| Rhythm Pharmaceuticals, Inc. | $3,386 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72,166 | 95 | Novo Nordisk Inc ($26,700) |
| 2023 | $62,214 | 106 | Novo Nordisk Inc ($29,257) |
| 2022 | $110,744 | 157 | Novo Nordisk Inc ($65,114) |
| 2021 | $116,448 | 174 | Novo Nordisk Inc ($66,322) |
| 2020 | $43,500 | 105 | Novo Nordisk Inc ($22,685) |
| 2019 | $66,987 | 156 | Janssen Pharmaceuticals, Inc ($35,918) |
| 2018 | $67,516 | 184 | Janssen Pharmaceuticals, Inc ($50,437) |
| 2017 | $105,523 | 152 | Janssen Pharmaceuticals, Inc ($78,841) |
All Payment Transactions
1,129 individual payment records from CMS Open Payments — Page 1 of 46
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $115.55 | General |
| Category: Cardio-renal | ||||||
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Endocrinology | ||||||
| 12/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $141.16 | General |
| 12/05/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: DIABETES | ||||||
| 11/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: Diabetes | ||||||
| 11/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Diabetes | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: DIABETES | ||||||
| 11/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | Cash or cash equivalent | $119.21 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Cardio-renal | ||||||
| 11/08/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 11/08/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Obesity | ||||||
| 11/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Diabetes | ||||||
| 11/07/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 10/24/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $66.44 | General |
| 10/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Diabetes | ||||||
| 10/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $121.16 | General |
| Category: DIABETES | ||||||
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: DIABETES | ||||||
| 10/03/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 10/02/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 10/02/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 10/01/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $938.00 | General |
| Category: Diabetes | ||||||
| 09/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,380.00 | General |
| Category: Cardio-renal | ||||||
| 09/27/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: DIABETES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $3,638 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 41 | 3,374 | 7,958 | $596,355 | $254,962 |
| 2022 | 35 | 1,924 | 4,131 | $364,550 | $155,074 |
| 2021 | 32 | 3,072 | 7,329 | $604,560 | $272,306 |
| 2020 | 29 | 2,353 | 5,937 | $540,065 | $230,184 |
Total Patients
10,723
Total Services
25,355
Medicare Billing
$912,526
Procedure Codes
137
All Medicare Procedures & Services
137 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 309 | 593 | $109,705 | $51,291 | 46.8% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 101 | 1,076 | $80,700 | $32,819 | 40.7% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 105 | 656 | $59,040 | $24,189 | 41.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 88 | 507 | $53,235 | $18,930 | 35.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 780 | $35,100 | $14,487 | 41.3% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 132 | 136 | $27,200 | $11,162 | 41.0% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 54 | 242 | $25,410 | $10,648 | 41.9% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 39 | 258 | $25,800 | $9,522 | 36.9% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 39 | 141 | $14,100 | $6,878 | 48.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 69 | 69 | $17,250 | $6,605 | 38.3% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 49 | 61 | $13,115 | $6,224 | 47.5% |
| 82306 | Vitamin d-3 level | Office | 2023 | 178 | 214 | $12,840 | $6,064 | 47.2% |
| 76982 | Ultrasound scan of growth for measuring elasticity, first growth | Office | 2023 | 78 | 80 | $13,200 | $5,794 | 43.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 206 | 308 | $10,780 | $4,969 | 46.1% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 201 | 303 | $10,605 | $4,929 | 46.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 286 | 462 | $6,685 | $3,865 | 57.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 25 | $6,250 | $3,498 | 56.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $6,300 | $3,330 | 52.9% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 85 | 126 | $6,930 | $3,265 | 47.1% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 53 | 54 | $7,560 | $2,905 | 38.4% |
| 76983 | Ultrasound scan of growth for measuring elasticity, each additional growth | Office | 2023 | 47 | 62 | $6,510 | $2,884 | 44.3% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 209 | 314 | $6,280 | $2,721 | 43.3% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 117 | 140 | $4,200 | $2,029 | 48.3% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 24 | 24 | $4,200 | $1,953 | 46.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 134 | 205 | $4,100 | $1,902 | 46.4% |
About Dr. Gloria Ortiz, M.D
Dr. Gloria Ortiz, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Mcallen, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2010. The National Provider Identifier (NPI) number assigned to this provider is 1871825307.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gloria Ortiz, M.D has received a total of $645,097 in payments from pharmaceutical and medical device companies, with $72,166 received in 2024. These payments were reported across 1,129 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($541,357).
As a Medicare-enrolled provider, Ortiz has provided services to 10,723 Medicare beneficiaries, totaling 25,355 services with total Medicare billing of $912,526. Data is available for 4 years (2020–2023), covering 137 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Mcallen, TX
- Active Since 02/09/2010
- Last Updated 10/22/2019
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1871825307
Products in Payments
- INVOKANA (Drug) $171,907
- JARDIANCE (Drug) $137,624
- Ozempic (Drug) $69,625
- Rybelsus (Drug) $66,136
- Kerendia (Drug) $50,100
- RYBELSUS (Drug) $47,175
- GVOKE PFS (Drug) $18,146
- SOLIQUA 100/33 (Biological) $15,184
- TOUJEO (Biological) $14,718
- Wegovy (Drug) $13,542
- Victoza (Drug) $4,536
- DISEASE STATE (Drug) $2,648
- Saxenda (Drug) $2,197
- Imcivree (Drug) $1,788
- Eversense (Device) $400.00
- FreeStyle Libre blood glucose Flash Monitoring System (Device) $387.53
- FreeStyle Libre (Device) $386.41
- FARXIGA (Drug) $283.52
- Vascepa (Drug) $277.63
- Omnipod (Device) $200.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Mcallen
Dr. Maria Naranjo Palacio, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1,009
Endocrinology, Diabetes & Metabolism $1,009
Dr. Zain Gulzar, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $18.08
Endocrinology, Diabetes & Metabolism $18.08
Dr. Raul Pinto, M.d, M.D
Endocrinology, Diabetes & Metabolism
Endocrinology, Diabetes & Metabolism